DE68929096T2
(de)
|
1988-09-01 |
2000-05-11 |
Bayer Ag |
Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
|
US6051231A
(en)
*
|
1988-09-01 |
2000-04-18 |
Bayer Corporation |
Antiviral methods and prepations
|
US6514936B1
(en)
|
1988-09-01 |
2003-02-04 |
Bayer Corporation |
Antiviral methods using human rhinovirus receptor (ICAM-1)
|
US6143298A
(en)
*
|
1988-09-01 |
2000-11-07 |
Bayer Corporation |
Soluble truncated forms of ICAM-1
|
IE62496B1
(en)
*
|
1990-04-19 |
1995-02-08 |
Res Dev Foundation |
Antibody conjugates for treatment of neoplastic disease
|
US20030064480A1
(en)
*
|
1990-06-28 |
2003-04-03 |
Leander Lauffer |
Fusion proteins with immunoglobulin portions, the preparation and use thereof
|
US6107461A
(en)
*
|
1990-07-20 |
2000-08-22 |
Bayer Corporation |
Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
|
US6130202A
(en)
*
|
1990-07-20 |
2000-10-10 |
Bayer Corporation |
Antiviral methods
|
DK0468257T3
(da)
*
|
1990-07-20 |
2000-03-27 |
Bayer Ag |
Multimer form af human rhinovirusreceptorprotein
|
US6407221B1
(en)
*
|
1990-12-14 |
2002-06-18 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
US6605712B1
(en)
*
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US6753162B1
(en)
|
1991-03-07 |
2004-06-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
US5843728A
(en)
*
|
1991-03-07 |
1998-12-01 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US5912170A
(en)
*
|
1991-03-07 |
1999-06-15 |
The General Hospital Corporation |
Redirection of cellular immunity by protein-tyrosine kinase chimeras
|
US5851828A
(en)
|
1991-03-07 |
1998-12-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
IE920716A1
(en)
*
|
1991-03-07 |
1992-09-09 |
Gen Hospital Corp |
Redirection of cellular immunity by receptor chimeras
|
WO1993010218A1
(en)
*
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
IL104570A0
(en)
*
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
DE69334150T2
(de)
*
|
1992-05-14 |
2008-03-13 |
Baylor College Of Medicine, Houston |
Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
|
CA2170980A1
(en)
*
|
1993-09-03 |
1995-03-09 |
James Mule |
Genetically modified human hematopoietic stem cells and their progeny
|
AU2207195A
(en)
*
|
1994-04-05 |
1995-10-23 |
Board Of Regents, The University Of Texas System |
Modified receptors that continuously signal
|
ES2185705T3
(es)
*
|
1994-05-02 |
2003-05-01 |
Bernd Groner |
Proteina bifuncional, preparacion y uso.
|
US5972627A
(en)
*
|
1994-06-15 |
1999-10-26 |
Systemix, Inc. |
Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby
|
US5985660A
(en)
*
|
1994-06-15 |
1999-11-16 |
Systemix, Inc. |
Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
|
WO1996013584A1
(en)
*
|
1994-11-01 |
1996-05-09 |
Targeted Genetics Corporation |
Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
WO1996018105A1
(en)
*
|
1994-12-06 |
1996-06-13 |
The President And Fellows Of Harvard College |
Single chain t-cell receptor
|
US5741899A
(en)
*
|
1995-02-02 |
1998-04-21 |
Cell Genesys, Inc. |
Chimeric receptors comprising janus kinase for regulating cellular pro liferation
|
US5712149A
(en)
*
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
US6103521A
(en)
*
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
US5891680A
(en)
*
|
1995-02-08 |
1999-04-06 |
Whitehead Institute For Biomedical Research |
Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
|
CA2209300C
(en)
*
|
1995-02-24 |
2011-06-28 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US5830755A
(en)
*
|
1995-03-27 |
1998-11-03 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
T-cell receptors and their use in therapeutic and diagnostic methods
|
AU712415B2
(en)
*
|
1995-04-04 |
1999-11-04 |
Cell Genesys, Inc. |
Transplantation of genetically modified cells having low levels of class I MHC proteins on the cell surface
|
US5866416A
(en)
*
|
1995-04-07 |
1999-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Cell line for propagating receptor binding site-deleted FMDV
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
US6015554A
(en)
*
|
1995-06-07 |
2000-01-18 |
Systemix, Inc. |
Method of reconstituting human lymphoid and dendritic cells
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6017754A
(en)
*
|
1995-08-24 |
2000-01-25 |
Invitrogen Corporation |
System for isolating and identifying eukaryotic cells transfected with genes and vectors, host cells and methods thereof
|
DE19540515C1
(de)
*
|
1995-10-31 |
1997-02-06 |
Boehringer Ingelheim Int |
Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten
|
WO1997020048A2
(en)
*
|
1995-11-30 |
1997-06-05 |
Bristol-Myers Squibb Company |
Modified sfv molecules which mediate adhesion between cells and uses thereof
|
US6699715B1
(en)
|
1995-11-30 |
2004-03-02 |
Bristol-Myers Squibb Co. |
Modified sFv molecules which mediate adhesion between cells and uses thereof
|
AU1821397A
(en)
*
|
1995-12-21 |
1997-11-07 |
Scripps Research Institute, The |
Targeted therapeutic or diagnostic agents and methods of making and using same
|
GB9526131D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US7084252B1
(en)
|
1996-01-16 |
2006-08-01 |
The Rockefeller University |
DB, the receptor for leptin
|
US7063958B1
(en)
|
1996-01-16 |
2006-06-20 |
The Rockefeller University |
Nucleic acids db, the receptor for leptin
|
US7148004B1
(en)
*
|
1997-01-16 |
2006-12-12 |
The Rockefeller University |
Oligonucleotides of the OB-R isoforms and methods of diagnosing body weight
|
PT879282E
(pt)
|
1996-01-17 |
2003-11-28 |
Imp College Innovations Ltd |
Imunoterapia utilizando linfocitos t citotoxicos (ctl)
|
US7619079B2
(en)
*
|
1996-02-14 |
2009-11-17 |
The Rockefeller University |
Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof
|
US6733746B2
(en)
*
|
1996-03-12 |
2004-05-11 |
Invitrogen Corporation |
Hematopoietic cell culture nutrient supplement
|
WO1997034634A1
(en)
*
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Single chain fv constructs of anti-ganglioside gd2 antibodies
|
US6060054A
(en)
*
|
1996-04-10 |
2000-05-09 |
National Jewish Medical And Research Center |
Product for T lymphocyte immunosuppression
|
AU2728297A
(en)
*
|
1996-04-15 |
1997-11-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Soluble 7-transmembrane domain G-protein-coupled receptor compositions and me thods
|
EP0937095A4
(de)
*
|
1996-10-25 |
1999-12-22 |
Cell Genesys Inc |
Gezielte zytolyse von krebszellen
|
US5969102A
(en)
|
1997-03-03 |
1999-10-19 |
St. Jude Children's Research Hospital |
Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
|
CA2311574A1
(en)
|
1997-12-02 |
1999-06-10 |
Medarex, Inc. |
Cells expressing anti-fc receptor binding components
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
CA2323776C
(en)
|
1998-03-19 |
2010-04-27 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
GB9809658D0
(en)
*
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
US6410319B1
(en)
|
1998-10-20 |
2002-06-25 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
ES2293748T3
(es)
*
|
1998-10-21 |
2008-03-16 |
Altor Bioscience Corporation |
Moleculas de fijacion poliespecificas y usos de las mismas.
|
US6855549B1
(en)
|
1998-11-23 |
2005-02-15 |
The University Of Iowa Research Foundation |
Methods and compositions for increasing the infectivity of gene transfer vectors
|
US6156515A
(en)
*
|
1999-02-09 |
2000-12-05 |
Urocor, Inc. |
Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
|
EP2357192A1
(de)
|
1999-02-26 |
2011-08-17 |
Human Genome Sciences, Inc. |
Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
|
US6221597B1
(en)
|
1999-05-21 |
2001-04-24 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
US6200803B1
(en)
|
1999-05-21 |
2001-03-13 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
US6197517B1
(en)
|
1999-05-21 |
2001-03-06 |
Rosetta Inpharmatics, Inc. |
Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs
|
EP1754488A1
(de)
|
1999-05-24 |
2007-02-21 |
Introgen Therapeutics, Inc. |
Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
EP1189634B1
(de)
*
|
1999-06-25 |
2007-02-28 |
Genentech, Inc. |
Behandlung von prostata-krebs mit anti-erbb2 antikörpern
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
CA2382045A1
(en)
*
|
1999-08-20 |
2001-03-01 |
Board Of Regents, The University Of Texas System |
Hdac4 and hdac5 in the regulation of cardiac gene expression
|
DE60042693D1
(de)
*
|
1999-08-27 |
2009-09-17 |
Genentech Inc |
Dosierung für die behandlung mit anti erbb2-antikörpern
|
JP2003521910A
(ja)
*
|
2000-02-11 |
2003-07-22 |
ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド |
網膜幹細胞の分離及び移植
|
WO2001083781A2
(en)
*
|
2000-04-28 |
2001-11-08 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
ES2331646T3
(es)
|
2000-05-19 |
2010-01-12 |
Genentech, Inc. |
Ensayo para la deteccion de genes para mejorar la probabilidad de una respuesta eficaz a una terapia contra el cancer basada en antagonistas de erbb.
|
IL136511A0
(en)
|
2000-06-01 |
2001-06-14 |
Gavish Galilee Bio Appl Ltd |
Genetically engineered mhc molecules
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
WO2002002641A1
(en)
|
2000-06-16 |
2002-01-10 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to blys
|
EP1334188B1
(de)
*
|
2000-11-07 |
2006-08-30 |
City of Hope |
Cd19-spezifische umgezielte immunzellen
|
JP4434580B2
(ja)
|
2000-11-28 |
2010-03-17 |
メディミューン,エルエルシー |
予防及び治療のために抗rsv抗体を投与/処方する方法
|
EP2354149B1
(de)
|
2000-12-12 |
2017-08-30 |
MedImmune, LLC |
Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
|
EP1683865A3
(de)
|
2001-02-02 |
2006-10-25 |
Eli Lilly & Company |
Säugerproteine und insbesondere CD200
|
US7175988B2
(en)
*
|
2001-02-09 |
2007-02-13 |
Human Genome Sciences, Inc. |
Human G-protein Chemokine Receptor (CCR5) HDGNR10
|
ZA200305980B
(en)
*
|
2001-02-12 |
2007-01-31 |
Res Dev Foundation |
Modified proteins, designer toxins, and methods of making thereof
|
US20030044406A1
(en)
*
|
2001-03-02 |
2003-03-06 |
Christine Dingivan |
Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
|
AU2002250293B2
(en)
|
2001-03-09 |
2007-10-11 |
Arnason, Barry G. Mr |
Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
|
US8163289B2
(en)
|
2001-03-09 |
2012-04-24 |
Iterative Therapeutics, Inc. |
Methods and compositions involving polymeric immunoglobulin fusion proteins
|
US7723111B2
(en)
|
2001-03-09 |
2010-05-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Activated dual specificity lymphocytes and their methods of use
|
JP2004532213A
(ja)
*
|
2001-04-06 |
2004-10-21 |
ザ ユニヴァーシティ オヴ シカゴ |
Egr−1プロモーター活性の化学療法誘導
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
ATE470676T1
(de)
|
2001-04-13 |
2010-06-15 |
Human Genome Sciences Inc |
Anti-vegf-2 antikörper
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
AU2007237297B2
(en)
*
|
2001-04-30 |
2010-12-16 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
US11278594B2
(en)
|
2001-04-30 |
2022-03-22 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
AU2002256390B2
(en)
*
|
2001-04-30 |
2007-08-30 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
US7514537B2
(en)
*
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
MXPA03010747A
(es)
|
2001-05-25 |
2004-03-02 |
Human Genome Sciences Inc |
Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
|
AU2002327310B2
(en)
|
2001-07-17 |
2006-09-28 |
Research Development Foundation |
Therapeutic agents comprising pro-apoptotic proteins
|
US6867189B2
(en)
*
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
US20030148982A1
(en)
*
|
2001-11-13 |
2003-08-07 |
Brenner Malcolm K. |
Bi-spcific chimeric T cells
|
JP2005523688A
(ja)
*
|
2002-01-18 |
2005-08-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
タンパク質チロシンキナーゼおよび/またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
|
WO2003070889A2
(en)
*
|
2002-02-19 |
2003-08-28 |
Idec Pharmaceuticals Corporation |
Prostate specific genes and the use thereof in design or therapeutics
|
EP1497445A2
(de)
*
|
2002-04-01 |
2005-01-19 |
Human Genome Sciences, Inc. |
Spezifisch an gmad bindende antikörper
|
WO2003086458A1
(en)
|
2002-04-12 |
2003-10-23 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
AU2003228751A1
(en)
|
2002-05-01 |
2003-11-17 |
Cell Genesys, Inc. |
Lentiviral vector particles resistant to complement inactivation
|
ES2377720T3
(es)
|
2002-05-10 |
2012-03-30 |
Purdue Research Foundation |
Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos.
|
US7446190B2
(en)
*
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
WO2003105761A2
(en)
*
|
2002-06-12 |
2003-12-24 |
Research Development Foundation |
Immunotoxin as a therapeutic agent and uses thereof
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
CA2495251C
(en)
|
2002-08-14 |
2018-03-06 |
Macrogenics, Inc. |
Fc.gamma.riib-specific antibodies and methods of use thereof
|
US20050272029A1
(en)
*
|
2002-08-16 |
2005-12-08 |
Bertrand Saunier |
Hepatitis c viral-like particle purification
|
EP2298806A1
(de)
|
2002-10-16 |
2011-03-23 |
Purdue Pharma L.P. |
Antikörper, die an zellassoziiertes CA 125/0722P binden, und Verfahren zu deren Anwendung
|
WO2004043397A2
(en)
*
|
2002-11-12 |
2004-05-27 |
Genentech, Inc. |
Compositions and methods for the treatment of rheumatoid arthritis
|
EP1572972A4
(de)
*
|
2002-11-21 |
2007-11-21 |
Genentech Inc |
Therapie nichtmaligner krankheiten oder störungen mit anti-erbb2-antikörpern
|
US20050265992A1
(en)
*
|
2003-01-03 |
2005-12-01 |
The Research Foundation Of State University Of New York |
F11 receptor (F11R) antagonists as therapeutic agents
|
US8557957B2
(en)
|
2003-01-03 |
2013-10-15 |
Elizabeth Kornecki |
Methods of treating disorders by administration of F11 receptor antagonists
|
EP1585815A4
(de)
*
|
2003-01-21 |
2006-02-22 |
Bristol Myers Squibb Co |
Ein neues acyl-coenzym a, monoacylglycerin-acyltransferase-3 (mgat3), codierendes polynukleotid sowie verwendungen davon
|
ES2347959T3
(es)
|
2003-02-20 |
2010-11-26 |
Seattle Genetics, Inc. |
Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer.
|
KR20110094361A
(ko)
|
2003-04-11 |
2011-08-23 |
메디뮨 엘엘씨 |
재조합 il9 항체 및 그의 용도
|
AU2004286198C1
(en)
|
2003-08-18 |
2011-02-24 |
Medimmune, Llc |
Humanization of antibodies
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
US20130266551A1
(en)
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
US20050113564A1
(en)
*
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
WO2005058961A2
(en)
*
|
2003-12-12 |
2005-06-30 |
Amgen Inc. |
Antibodies specific for human galanin, and uses thereof
|
EP1786463A4
(de)
*
|
2004-03-26 |
2009-05-20 |
Human Genome Sciences Inc |
Antikörper gegen nogo-rezeptor
|
US20050238628A1
(en)
*
|
2004-04-08 |
2005-10-27 |
Blau Carl A |
Methods for treating cancer
|
ES2353606T3
(es)
*
|
2004-08-25 |
2011-03-03 |
The University Of Chicago |
Uso de la combinación que comprende temozolomida y tnf-alfa para el tratamiento del gioblastoma.
|
WO2006034292A2
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US7994298B2
(en)
|
2004-09-24 |
2011-08-09 |
Trustees Of Dartmouth College |
Chimeric NK receptor and methods for treating cancer
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
WO2006052960A2
(en)
*
|
2004-11-08 |
2006-05-18 |
The General Hospital Corporation |
METHODS AND COMPOSITIONS FOR INCREASING STEM CELL HOMING USING Gαs ACTIVATORS
|
AU2006210769A1
(en)
*
|
2005-02-01 |
2006-08-10 |
Research Development Foundation |
BLyS fusion proteins for targeting BLyS receptor and methods for treatment of B-cell proliferative disorders
|
CA2602035C
(en)
|
2005-03-18 |
2015-06-16 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
ES2561628T3
(es)
|
2005-05-06 |
2016-02-29 |
Zymogenetics, Inc. |
Anticuerpos monoclonales IL-31 y métodos de uso
|
AU2005332058B2
(en)
|
2005-05-19 |
2011-12-01 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention |
Functional epitopes of Streptococcus pneumoniae PsaA antigen and uses thereof
|
EP1893647A2
(de)
|
2005-06-23 |
2008-03-05 |
MedImmune, Inc. |
Antikörperformulierungen mit optimierten aggregations- und fragmentierungsprofilen
|
WO2007008604A2
(en)
*
|
2005-07-08 |
2007-01-18 |
Bristol-Myers Squibb Company |
Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
|
US7713521B2
(en)
*
|
2005-08-12 |
2010-05-11 |
Schering Corporation |
MCP1 fusions
|
US20070202512A1
(en)
*
|
2005-08-19 |
2007-08-30 |
Bristol-Myers Squibb Company |
Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
|
CA2628238A1
(en)
|
2005-11-07 |
2007-05-18 |
The Scripps Research Institute |
Compositions and methods for controlling tissue factor signaling specificity
|
CA2650730A1
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
AU2007248019B2
(en)
*
|
2006-05-03 |
2012-10-11 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Chimeric T cell receptors and related materials and methods of use
|
ES2599319T3
(es)
|
2006-06-26 |
2017-02-01 |
Macrogenics, Inc. |
Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
EP2064243A2
(de)
|
2006-08-28 |
2009-06-03 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistische lichtspezifische menschliche monoklonale antikörper
|
SI2594586T1
(sl)
|
2006-09-01 |
2014-11-28 |
Zymogenetics, Inc. |
IL-31 monoklonska protitelesa in metode uporabe
|
WO2008044869A1
(en)
|
2006-10-10 |
2008-04-17 |
Viromed Co., Ltd. |
Expression vectors with improved safety
|
EP2407548A1
(de)
|
2006-10-16 |
2012-01-18 |
MedImmune, LLC |
Moleküle mit reduzierter Halbwertzeit, Zusammensetzungen und ihre Verwendung
|
MX2009004664A
(es)
|
2006-11-02 |
2009-10-12 |
Daniel J Capon |
Inmunoglobulinas hibridas con partes moviles.
|
PT2099823E
(pt)
|
2006-12-01 |
2014-12-22 |
Seattle Genetics Inc |
Agentes de ligação ao alvo variantes e suas utilizações
|
US10155038B2
(en)
|
2007-02-02 |
2018-12-18 |
Yale University |
Cells prepared by transient transfection and methods of use thereof
|
US9249423B2
(en)
|
2007-02-02 |
2016-02-02 |
Yale University |
Method of de-differentiating and re-differentiating somatic cells using RNA
|
WO2008097926A2
(en)
*
|
2007-02-02 |
2008-08-14 |
Yale University |
Transient transfection with rna
|
US20100209434A1
(en)
|
2007-03-30 |
2010-08-19 |
Medimmune, Llc |
Antibody formulation
|
ES2540807T3
(es)
|
2007-05-04 |
2015-07-13 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa |
Dominios variables de anticuerpos de conejo modificados por ingeniería genética y usos de los mismos
|
NZ599278A
(en)
|
2007-05-14 |
2013-12-20 |
Medimmune Llc |
Methods of reducing eosinophil levels
|
US20080283557A1
(en)
*
|
2007-05-17 |
2008-11-20 |
Julianne Desautels |
Spout for food stuff container
|
CN101861391A
(zh)
|
2007-08-10 |
2010-10-13 |
韦恩州立大学 |
通过翻译调控基因表达系统检测和调节细胞死亡的组合物和方法
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
KR101603109B1
(ko)
|
2007-12-07 |
2016-03-25 |
지모제넥틱스, 인코포레이티드 |
Il-31에 특이적인 인간화된 항체 분자
|
US20090181409A1
(en)
*
|
2008-01-10 |
2009-07-16 |
Ye Fang |
Optical biosensor method for cell-cell interaction
|
WO2009092011A1
(en)
|
2008-01-18 |
2009-07-23 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
CA2723197C
(en)
|
2008-05-02 |
2017-09-19 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
SG10201405377XA
(en)
|
2008-08-05 |
2014-12-30 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
CA2736799A1
(en)
|
2008-08-25 |
2010-03-11 |
Burnham Institute For Medical Research |
Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
|
PL3006459T3
(pl)
|
2008-08-26 |
2022-01-17 |
City Of Hope |
Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US20110014190A1
(en)
|
2009-02-12 |
2011-01-20 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
WO2010141329A1
(en)
|
2009-06-01 |
2010-12-09 |
Medimmune, Llc |
Molecules with extended half-lives and uses thereof
|
US20120213705A1
(en)
|
2009-06-22 |
2012-08-23 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
JP5589077B2
(ja)
|
2009-07-20 |
2014-09-10 |
ブリストル−マイヤーズ スクイブ カンパニー |
増殖性疾患の相乗的処置のための抗ctla4抗体と多様な治療レジメンとの組み合わせ
|
DK2464657T3
(en)
|
2009-08-10 |
2015-06-29 |
Morphosys Ag |
New screening strategies for the identification of antibodies or fragments thereof which bind an antigen with enzymatic activity
|
JP5762408B2
(ja)
|
2009-08-13 |
2015-08-12 |
クルセル ホランド ベー ヴェー |
ヒト呼吸器合胞体ウイルス(rsv)に対する抗体および使用方法
|
JP5883384B2
(ja)
|
2009-08-13 |
2016-03-15 |
ザ ジョンズ ホプキンス ユニバーシティー |
免疫機能を調節する方法
|
US20110189183A1
(en)
|
2009-09-18 |
2011-08-04 |
Robert Anthony Williamson |
Antibodies against candida, collections thereof and methods of use
|
US9273283B2
(en)
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
CA2793959C
(en)
|
2010-03-25 |
2019-06-04 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
ES2659406T3
(es)
|
2010-05-06 |
2018-03-15 |
Novartis Ag |
Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
|
AU2011249782B2
(en)
|
2010-05-06 |
2014-10-02 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
|
US8524217B2
(en)
|
2010-05-11 |
2013-09-03 |
Merck Sharp & Dohme Corp. |
MCP1-Ig fusion variants
|
AU2011274414B2
(en)
|
2010-07-09 |
2016-10-06 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptides and methods of use thereof
|
CN103097412B
(zh)
|
2010-07-09 |
2016-08-10 |
克鲁塞尔荷兰公司 |
抗人呼吸道合胞病毒(rsv)抗体以及使用方法
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
CN103080134B
(zh)
|
2010-08-20 |
2015-11-25 |
诺华股份有限公司 |
表皮生长因子受体3(her3)的抗体
|
PE20140190A1
(es)
|
2010-08-27 |
2014-02-10 |
Stem Centrx Inc |
Moduladores de proteinas notum y metodos de uso
|
US9458231B2
(en)
|
2010-09-03 |
2016-10-04 |
Stemcentrx, Inc. |
Modulators and methods of use
|
EP2621514B1
(de)
|
2010-09-28 |
2016-09-21 |
KAHR Medical (2005) Ltd |
Zusammensetzungen und verfahren zur behandlung von hämatologischen malignomen
|
MX352929B
(es)
|
2010-11-05 |
2017-12-13 |
Zymeworks Inc |
DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
|
EP2643353A1
(de)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispezifische moleküle
|
EP2648748A1
(de)
|
2010-12-08 |
2013-10-16 |
Stem Centrx, Inc. |
Neuartige modulatoren und verfahren zu ihrer verwendung
|
PT3214091T
(pt)
|
2010-12-09 |
2019-01-11 |
Univ Pennsylvania |
Utilização de células t modificadas por recetor de antigénio quimérico para tratar o cancro
|
WO2012103165A2
(en)
|
2011-01-26 |
2012-08-02 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies and uses thereof
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
AU2012267786B2
(en)
|
2011-06-10 |
2017-08-03 |
Oregon Health & Science University |
CMV glycoproteins and recombinant vectors
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
WO2013043071A1
(en)
|
2011-09-23 |
2013-03-28 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa |
Modified albumin-binding domains and uses thereof to improve pharmacokinetics
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
CN104053671A
(zh)
|
2011-11-01 |
2014-09-17 |
生态学有限公司 |
治疗癌症的抗体和方法
|
WO2013067055A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
US9220774B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Methods of treating cancer by administering anti-GPR49 antibodies
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
DK2773671T3
(da)
|
2011-11-04 |
2021-11-15 |
Zymeworks Inc |
Udformning af stabilt heterodimert antistof med mutationer i fc-domænet
|
EP2773669B1
(de)
|
2011-11-04 |
2018-03-28 |
Novartis AG |
Halbwertszeitverlängerer für ldl-verwandtes protein (6) lrp6
|
WO2013081993A1
(en)
|
2011-12-02 |
2013-06-06 |
Eli Lilly And Company |
Anti-glucagon antibodies and uses thereof
|
KR20140103135A
(ko)
|
2011-12-05 |
2014-08-25 |
노파르티스 아게 |
Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
|
JP6243345B2
(ja)
|
2011-12-05 |
2017-12-06 |
ノバルティス アーゲー |
上皮細胞増殖因子受容体3(her3)に対する抗体
|
CN106831985A
(zh)
|
2011-12-21 |
2017-06-13 |
诺华股份有限公司 |
用于抗体靶定p因子的组合物和方法
|
US11147852B2
(en)
|
2011-12-23 |
2021-10-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
KR20140144680A
(ko)
|
2012-02-17 |
2014-12-19 |
더 셰펜스 아이 리써치 인스티튜트 |
인간의 망막 전구세포의 표현형 프로필
|
BR112014020826A8
(pt)
|
2012-02-24 |
2017-09-19 |
Stem Centrx Inc |
Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
|
CN104334580B
(zh)
|
2012-02-24 |
2018-03-30 |
艾伯维施特姆森特克斯有限责任公司 |
抗sez6抗体及使用方法
|
US20130336973A1
(en)
|
2012-05-10 |
2013-12-19 |
Zymeworks Inc. |
Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain
|
EP3279315A3
(de)
|
2012-05-25 |
2018-02-28 |
Cellectis |
Verwendung von prä-alpha-t oder einer funktionellen variante davon zur erweiterung von t-zellen mit tcr-alpha-mangel
|
EP2679596B1
(de)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 Env-proteinvariante
|
EP4063391A1
(de)
|
2012-07-25 |
2022-09-28 |
Celldex Therapeutics, Inc. |
Anti-kit-antikörper und verwendungen davon
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
AU2013329311A1
(en)
|
2012-10-09 |
2015-04-30 |
Igenica Biotherapeutics, Inc. |
Anti-C16orf54 antibodies and methods of use thereof
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
CN104968678B
(zh)
|
2012-12-05 |
2018-12-11 |
诺华股份有限公司 |
靶向epo的抗体的组合物和方法
|
MX2015007931A
(es)
|
2012-12-18 |
2015-10-05 |
Novartis Ag |
Composiciones y metodos que utilizan una etiqueta de peptido que se une a hialuronano.
|
WO2014099671A1
(en)
*
|
2012-12-20 |
2014-06-26 |
Bluebird Bio, Inc. |
Chimeric antigen receptors and immune cells targeting b cell malignancies
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
CN110423282B
(zh)
|
2013-02-15 |
2023-09-08 |
加利福尼亚大学董事会 |
嵌合抗原受体及其使用方法
|
ES2760023T3
(es)
|
2013-02-20 |
2020-05-12 |
Univ Pennsylvania |
Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado
|
TW201446794A
(zh)
|
2013-02-20 |
2014-12-16 |
Novartis Ag |
利用抗-cd123嵌合抗原受體工程化t細胞之初級人類白血病有效靶向
|
RS58873B1
(sr)
|
2013-02-22 |
2019-08-30 |
Abbvie Stemcentrx Llc |
Antidll3-antitelo-pbd konjugati i njihova upotreba
|
DK2970473T3
(da)
|
2013-03-14 |
2017-11-27 |
Bristol Myers Squibb Co |
Kombination af dr5-agonist og anti-pd-1-antagonist og fremgangsmåder til anvendelse heraf
|
EP2970479B1
(de)
|
2013-03-14 |
2019-04-24 |
Novartis AG |
Antikörper gegen notch 3
|
ES2759061T3
(es)
|
2013-03-15 |
2020-05-07 |
Biomolecular Holdings Llc |
Inmunoglobulina híbrida que contiene unión no peptidílica
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
CA2899089C
(en)
|
2013-03-15 |
2021-10-26 |
Biogen Ma Inc. |
Factor ix polypeptide formulations
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
US9562101B2
(en)
|
2013-06-21 |
2017-02-07 |
Novartis Ag |
Lectin-like oxidized LDL receptor 1 antibodies and methods of use
|
AU2014332442B2
(en)
|
2013-08-26 |
2019-12-19 |
Biontech Research And Development, Inc. |
Nucleic acids encoding human antibodies to Sialyl-Lewis
|
ES2871418T3
(es)
|
2013-08-28 |
2021-10-28 |
Abbvie Stemcentrx Llc |
Composiciones y métodos de conjugación de anticuerpos específicos de sitio
|
EP3338793A1
(de)
|
2013-08-28 |
2018-06-27 |
AbbVie Stemcentrx LLC |
Neuartige sez6-modulatoren und verfahren zur verwendung
|
EP2848937A1
(de)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
BR112016010051A2
(pt)
|
2013-11-04 |
2017-12-05 |
Pfizer |
?conjugados de anticorpo-fármaco anti-efna4?
|
EP3083964B1
(de)
|
2013-12-19 |
2022-01-26 |
Novartis AG |
Menschliche chimäre mesothelin-antigenrezeptoren und verwendungen davon
|
EP3087101A4
(de)
|
2013-12-20 |
2017-12-06 |
Novartis AG |
Regulierbarer chimärer antigenrezeptor
|
BR112016015881A2
(pt)
|
2014-01-08 |
2017-09-19 |
1Globe Biomedical Co Ltd |
Tecnologia inédita de adcc baseada em biologia sintética
|
ES2963718T3
(es)
|
2014-01-21 |
2024-04-01 |
Novartis Ag |
Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
|
EP3738981A1
(de)
|
2014-01-24 |
2020-11-18 |
NGM Biopharmaceuticals, Inc. |
Beta-klotho 2 bindende antikörper und verfahren zur verwendung davon
|
AU2015218633A1
(en)
|
2014-02-21 |
2016-09-01 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibodies and drug conjugates for use in melanoma
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
NZ724904A
(en)
|
2014-03-14 |
2023-04-28 |
Biomolecular Holdings Llc |
Hybrid immunoglobulin containing non-peptidyl linkage
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
KR102352573B1
(ko)
|
2014-04-04 |
2022-01-18 |
바이오노믹스 인코포레이티드 |
Lgr5에 결합하는 인간화된 항체들
|
KR102487608B1
(ko)
|
2014-04-07 |
2023-01-12 |
노파르티스 아게 |
항-cd19 키메라 항원 수용체를 사용한 암의 치료
|
MX2016014824A
(es)
|
2014-05-13 |
2017-03-23 |
Bioatla Llc |
Proteinas biologicas condicionalmente activas.
|
WO2015174928A1
(en)
|
2014-05-15 |
2015-11-19 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
WO2015175874A2
(en)
|
2014-05-16 |
2015-11-19 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
CA2950602C
(en)
|
2014-06-04 |
2021-07-20 |
MabVax Therapeutics, Inc. |
Human monoclonal antibodies to ganglioside gd2
|
EP3160990A2
(de)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Zusammensetzungen und verfahren für proteine mit langer wirkung
|
US20170327553A1
(en)
|
2014-06-25 |
2017-11-16 |
Novartis Ag |
Compositions and methods for long acting proteins
|
EP3171882A1
(de)
|
2014-07-21 |
2017-05-31 |
Novartis AG |
Behandlung von krebs mit einem chimären cll-1-antigenrezeptor
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用cd33嵌合抗原受體治療癌症
|
CA2955386A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
JP6649358B2
(ja)
|
2014-08-07 |
2020-02-19 |
ノバルティス アーゲー |
アンジオポエチン様4抗体および使用法
|
US9988443B2
(en)
|
2014-08-07 |
2018-06-05 |
Novartis Ag |
Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
|
CN112410363A
(zh)
|
2014-08-19 |
2021-02-26 |
诺华股份有限公司 |
抗cd123嵌合抗原受体(car)用于癌症治疗
|
EP3189152A4
(de)
|
2014-09-03 |
2018-04-04 |
BioAtla LLC |
Entdeckung und herstellung von bedingt aktiven biologischen proteinen in denselben wirten zur herstellung eukaryontischer zellen
|
ES2891332T3
(es)
|
2014-09-17 |
2022-01-27 |
Novartis Ag |
Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
|
BR122024000360A2
(pt)
|
2014-09-19 |
2024-02-27 |
City Of Hope |
Molécula de ácido nucleico, população de células t humanas transduzidas por um vetor que compreende um cassete de expressão que codifica um receptor de antígeno quimérico e seu uso
|
EP3204777A1
(de)
|
2014-10-08 |
2017-08-16 |
Novartis AG |
Prädiktive biomarker für das therapeutische ansprechen auf chimäre antigenrezeptortherapie und verwendung davon
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
EP3215139B1
(de)
|
2014-11-03 |
2020-08-19 |
Cerus Corporation |
Zusammensetzungen und verfahren für verbesserte car-t-zelltherapien
|
DK3689140T3
(da)
*
|
2014-11-24 |
2022-08-01 |
Regeneron Pharma |
Ikke-humane dyr, der eksprimerer humaniseret cd3-kompleks
|
KR20170087500A
(ko)
|
2014-12-11 |
2017-07-28 |
피에르 파브르 메디카먼트 |
항-c10orf54 항체들 및 그들의 용도들
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
US10273300B2
(en)
|
2014-12-29 |
2019-04-30 |
The Trustees Of The University Of Pennsylvania |
Methods of making chimeric antigen receptor-expressing cells
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
EP3262166A4
(de)
|
2015-02-24 |
2018-08-15 |
The Regents of The University of California |
Durch bindung ausgelöste, transkriptionelle schaltungen und verfahren zur verwendung davon
|
US10195272B2
(en)
*
|
2015-03-02 |
2019-02-05 |
The Nemours Foundation |
Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
|
FI3265123T3
(fi)
|
2015-03-03 |
2023-01-31 |
|
Vasta-aineita, käyttöjä & menetelmiä
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP3072901A1
(de)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
HUE059218T2
(hu)
|
2015-04-08 |
2022-11-28 |
Novartis Ag |
CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
|
ES2948133T3
(es)
|
2015-04-17 |
2023-08-31 |
Novartis Ag |
Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
|
WO2016179518A2
(en)
|
2015-05-06 |
2016-11-10 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
US9574014B2
(en)
*
|
2015-05-15 |
2017-02-21 |
City Of Hope |
Chimeric antigen receptor compositions
|
US10434153B1
(en)
|
2015-05-20 |
2019-10-08 |
Kim Leslie O'Neill |
Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
|
AU2016273028B2
(en)
|
2015-06-05 |
2019-02-14 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
US11236159B2
(en)
|
2015-08-03 |
2022-02-01 |
Novartis Ag |
Methods of treating FGF21-associated disorders
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
US11352439B2
(en)
*
|
2015-08-13 |
2022-06-07 |
Kim Leslie O'Neill |
Macrophage CAR (MOTO-CAR) in immunotherapy
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
CA2996635A1
(en)
|
2015-09-09 |
2017-03-16 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
US10000561B2
(en)
|
2015-09-09 |
2018-06-19 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
|
CA2997963A1
(en)
|
2015-09-29 |
2017-04-06 |
Celgene Corporation |
Pd-1 binding proteins and methods of use thereof
|
JP7064769B2
(ja)
|
2015-11-02 |
2022-05-11 |
バイオアトラ、エルエルシー |
条件的活性型ポリペプチド
|
UY37003A
(es)
|
2015-12-04 |
2017-06-30 |
Novartis Ag |
Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
JP2019506844A
(ja)
|
2015-12-18 |
2019-03-14 |
ノバルティス アーゲー |
CD32bを標的とする抗体およびその使用方法
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
KR20180096788A
(ko)
|
2016-01-08 |
2018-08-29 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
조건적 활성 이종이량체 폴리펩티드 및 이의 사용 방법
|
EP3851457A1
(de)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Gegen cll-1 gerichtete multispezifische moleküle
|
EP3410849B1
(de)
|
2016-02-05 |
2023-07-05 |
Institut Pasteur |
Verwendung von inhibitoren von adam12 als adjuvanzien in tumortherapien
|
CN108697799A
(zh)
|
2016-03-22 |
2018-10-23 |
生态学有限公司 |
抗lgr5单克隆抗体的施用
|
EP3432924A1
(de)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Zellsekretierte minikörper und verwendungen davon
|
CN109071647B
(zh)
|
2016-04-27 |
2022-11-22 |
诺华股份有限公司 |
抗生长分化因子15的抗体及其用途
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
WO2017216724A1
(en)
|
2016-06-15 |
2017-12-21 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
|
CN109641968B
(zh)
|
2016-07-06 |
2023-10-20 |
百时美施贵宝公司 |
Tim-4拮抗剂和pd-1拮抗剂的组合及其使用方法
|
CN110121352B
(zh)
|
2016-09-01 |
2020-12-11 |
嵌合体生物工程公司 |
Gold优化的car t-细胞
|
JP2019534859A
(ja)
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して白斑を治療する方法
|
US10751414B2
(en)
|
2016-09-19 |
2020-08-25 |
Celgene Corporation |
Methods of treating psoriasis using PD-1 binding antibodies
|
EP3523331A1
(de)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimäre antigenrezeptoren zur behandlung von krebs
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
JP7110199B2
(ja)
|
2016-12-23 |
2022-08-01 |
ノバルティス アーゲー |
抗第XI/XIa因子抗体による処置法
|
JP7139332B2
(ja)
|
2016-12-23 |
2022-09-20 |
ノバルティス アーゲー |
第xi因子抗体および使用方法
|
EP3579870A4
(de)
|
2017-02-07 |
2020-12-30 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Auf car-t-zell-tumor (ctct) abzielende phospholipidether (ple)-wirkstoffe
|
WO2018146594A1
(en)
|
2017-02-08 |
2018-08-16 |
Novartis Ag |
Fgf21 mimetic antibodies and uses thereof
|
CN110582288A
(zh)
|
2017-02-28 |
2019-12-17 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
BR112019018124A2
(pt)
|
2017-03-22 |
2020-04-07 |
Intellia Therapeutics Inc |
composições e métodos para imunooncologia
|
JP7256749B2
(ja)
|
2017-03-27 |
2023-04-12 |
ナショナル ユニヴァーシティー オブ シンガポール |
ナチュラルキラー細胞免疫療法における切断されたnkg2dキメラ受容体及びその使用
|
MX2019011570A
(es)
|
2017-03-27 |
2019-11-18 |
Nat Univ Singapore |
Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
|
US10415017B2
(en)
|
2017-05-17 |
2019-09-17 |
Thunder Biotech, Inc. |
Transgenic macrophages, chimeric antigen receptors, and associated methods
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
AU2018274216A1
(en)
|
2017-05-24 |
2019-12-12 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
JP2020520671A
(ja)
|
2017-05-24 |
2020-07-16 |
ノバルティス アーゲー |
抗体−サイトカイングラフト化タンパク質及び使用方法
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
KR20200125574A
(ko)
|
2017-07-18 |
2020-11-04 |
씨에스엘 베링 진 테라피, 인크. |
공여자 변형된 세포의 선택을 위해 조절가능한 스위치
|
CN111630069A
(zh)
|
2017-10-13 |
2020-09-04 |
勃林格殷格翰国际有限公司 |
针对Thomsen-nouvelle(Tn)抗原的人抗体
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
CN112292138A
(zh)
|
2018-01-22 |
2021-01-29 |
西雅图儿童医院(Dba西雅图儿童研究所) |
Car t细胞的使用方法
|
CA3093078A1
(en)
|
2018-03-06 |
2019-09-12 |
The Trustees Of The University Of Pennsylvania |
Prostate-specific membrane antigen cars and methods of use thereof
|
CN112004558A
(zh)
|
2018-04-12 |
2020-11-27 |
米迪亚制药有限责任公司 |
Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
|
EP3790607B1
(de)
|
2018-05-11 |
2023-12-27 |
Lupagen, Inc. |
Systeme für in sich geschlossene echtzeitänderungen von patientenzellen
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
PE20210320A1
(es)
|
2018-06-01 |
2021-02-16 |
Novartis Ag |
Moleculas de union contra bcma y usos de las mismas
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
EP3824287A1
(de)
|
2018-07-20 |
2021-05-26 |
Pierre Fabre Médicament |
Rezeptor für vista
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
WO2020180882A1
(en)
|
2019-03-05 |
2020-09-10 |
Nkarta, Inc. |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
JP2022524215A
(ja)
|
2019-03-28 |
2022-04-28 |
ダニスコ・ユーエス・インク |
改変抗体
|
WO2020236792A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
US20230071196A1
(en)
|
2019-05-21 |
2023-03-09 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
EP4090674A4
(de)
|
2020-01-14 |
2024-01-24 |
Synthekine Inc |
Vorgespannte il2-muteins-verfahren und -zusammensetzungen
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
EP4143236A1
(de)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Manipulierte immunglobuline
|
US20230167193A1
(en)
|
2020-05-01 |
2023-06-01 |
Novartis Ag |
Immunoglobulin variants
|
WO2022097060A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
WO2022147463A2
(en)
|
2020-12-31 |
2022-07-07 |
Alamar Biosciences, Inc. |
Binder molecules with high affinity and/ or specificity and methods of making and use thereof
|
KR20240025597A
(ko)
|
2021-06-29 |
2024-02-27 |
씨젠 인크. |
비푸코실화 항-cd70 항체 및 cd47 길항제의 조합으로 암을 치료하는 방법
|
US20230227545A1
(en)
|
2022-01-07 |
2023-07-20 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
US20230357381A1
(en)
|
2022-04-26 |
2023-11-09 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|